Aldeyra Therapeutics EPS ALDX

Diluted earnings per share by quarter and over the last twelve months, from 2013.

Aldeyra Therapeutics' earnings per share was −$0.39 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.09.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.09	n/a	−$0.39
Q1 FY26	Mar 31, 2026	−$0.06	n/a	−$0.46
Q4 FY25	Dec 31, 2025	−$0.11	n/a	−$0.57
Q3 FY25	Sep 30, 2025	−$0.13	n/a	−$0.73
Q2 FY25	Jun 30, 2025	−$0.16	n/a	−$0.85
Q1 FY25	Mar 31, 2025	−$0.17	n/a	−$0.97
Q4 FY24	Dec 31, 2024	−$0.27	n/a	−$0.94
Q3 FY24	Sep 30, 2024	−$0.25	n/a	−$0.75
Q2 FY24	Jun 30, 2024	−$0.28	n/a	−$0.64
Q1 FY24	Mar 31, 2024	−$0.14	n/a	−$0.51
Q4 FY23	Dec 31, 2023	−$0.08	n/a	−$0.64
Q3 FY23	Sep 30, 2023	−$0.14	n/a	−$0.78

Companies in Drug Manufacturers - General nearest Aldeyra Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
ALDXAldeyra Therapeutics	−$0.39
ATNMActinium Pharmaceuticals	$0.36
SPROSpero Therapeutics	$0.11
LFVNLifevantage	$0.40	−46% a year
NATRNatures Sunshine Products	$1.01	+36% a year
Peer median	$0.38

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.